---
id: antiviral-polymerase-inhibitors_263
category: antimicrobials
tags: [antivirals, polymerase-inhibitors, nucleoside-analogs, mechanism]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Antiviral Polymerase Inhibitors: Classification

**Q:** What are the 3 classes of viral polymerase inhibitors, and how do they differ mechanistically? (Use mnemonic **NNM**)

**A:**

| Class | Mechanism | Bioactivation | Examples | Viruses |
|-------|-----------|---------------|----------|---------|
| **N**ucleoside/Nucleotide Inhibitors (NIs) | **Chain terminators** → incorporated into viral DNA/RNA → halt elongation | Require phosphorylation by viral/cellular kinases | Acyclovir (DNA), remdesivir (RNA), sofosbuvir (HCV) | HSV, CMV, HBV, HCV, HIV, SARS-CoV-2 |
| **N**on-Nucleoside Inhibitors (NNIs) | **Allosteric inhibitors** → bind polymerase active site or PPi binding pocket | **No bioactivation needed** | Nevirapine (HIV RT), dasabuvir (HCV NS5B) | HIV, HCV |
| **M**utagenic Agents | Induce **error catastrophe** → excessive mutations → non-viable viral progeny | Require phosphorylation | Ribavirin, favipiravir, molnupiravir | Broad-spectrum RNA viruses |

**Key Statistics (2024):**
- **37 approved polymerase inhibitors** (as of Jan 2024)
- Target **9 human viruses** (DNA + RNA viruses)
- **Most common target:** RNA-dependent RNA polymerase (RdRp)

**Resistance:** Mutations in polymerase active site (e.g., YMDD mutation in HBV for lamivudine)

**Media:**

**Sources:** [PMC9654062 - Progression of Antiviral Agents Targeting Polymerases], [PMC11124969 - Small Molecule Drugs Targeting Viral Polymerases 2024], [PMC7975490 - Antiviral Mechanisms Review]
